Biotech · Private company · Juno Beach, FL, US
Aqualung Therapeutics Corp.
Track this companyFree. Adds Aqualung Therapeutics Corp. to your Dealase workspace and tells you when its record changes.
Clinical trials11 recruiting or active
Pipeline programs1From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline1
- ALT-100 mAbPhase 2 · Acute Respiratory Distress Syndrome (ARDS)ClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials1
- Study of Safety and Efficacy of ALT-100mAb in Participants With Moderate/Severe ARDSPHASE2 · ACTIVE_NOT_RECRUITING · started Dec 1, 2023ClinicalTrials.gov NCT05938036 · fetched Nov 12, 2026
NIH awards4
- Targeting eNAMPT-TLR4 signaling with the novel ALT-100 mAb to slow IPF progressionFiscal year 2025 · $284.7KNIH RePORTER 1R41HL180035-01 · fetched Nov 12, 2026
- Targeting the eNAMPT/TLR4 pathway to reduce Inflammatory Bowel Disease severityFiscal year 2024 · $975.2KNIH RePORTER 5R42DK135208-03 · fetched Nov 12, 2026
- Preclinical Development of a Novel eNAMPT-Neutralizing mAb for Pulmonary HypertensionFiscal year 2024 · $809KNIH RePORTER 5R42HL164300-03 · fetched Nov 12, 2026
- A Randomized Phase 2A Clinical Trial Pioneering the Utility of an eNAMPT-Reducing Therapy in ARDS/VILI: the PUERTA TrialFiscal year 2024 · $957.6KNIH RePORTER 5R44HL145930-05 · fetched Nov 12, 2026